Assignee: Teva Pharmaceutical Industries Ltd.

Location: Jerusalem, IL
No. of patents: 36

Browse patents
Browse applications

Number	Title	Issue Date
6528685	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, con...	03/04/2003
6316504	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing the same. The subject invention also provides methods of treating a subject afflicted with Parkin...	11/13/2001
6277886	Pharmaceutical compositions comprising S-(-)-N-propargyl-1-aminoindan Pharmaceutical compositions for the treatment of a neurological disorder of neurotrauma or for improving memory in a patient comprising a therapeutically effective amount of S-(-)-N-proparygl-1-aminoindan or a pharmaceutically acceptable salt thereof as a...	08/21/2001
6271263	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, con...	08/07/2001
6126968	Stable compositions containing N-propargyl-1-aminoindan A pharmaceutical composition comprising as active ingredient a racemic, S(-), and R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, and at least 60% by weight of at least one pentahydric or hexahydric alcohol. Optionally the com...	10/03/2000
5994408	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, con...	11/30/1999
5914349	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, con...	06/22/1999
5891923	R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia This invention relates to the use of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof for the treatment of dementia....	04/06/1999
5880159	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, con...	03/09/1999
5877218	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, con...	03/02/1999
5877221	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, con...	03/02/1999
5840756	Pharmaceutical composition of L-DOPA ester The present invention provides a pharmaceutical composition contains a thpeutically effective amount of L-DOPA ethyl ester and a carrier which comprises from 5.5 to 98.5% hydroxypropylmethyl cellulose, from 0.25 to 4.5% hydroxypropyl cellulose, and from ...	11/24/1998
5804573	Stabilized pharmaceutical composition containing derivative of vitamins D₂ and D₃ Pharmaceutically active derivatives of vitamin D2 and vitamin D3 in a solid state composition are stabilized by the presence of effective amounts of pharmaceutically acceptable antioxidant and polyoxyalkyl stabilizer. Specified antio...	09/08/1998
5786390	Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof....	07/28/1998
5744500	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson'...	04/28/1998
5668181	Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for the treatment of depression This invention relates to the use of R(+)-N-propargyl-1-aminoindan....	09/16/1997
5646188	Polyamine derivatives of 1-aminoindan A compound of general formula I ##STR1## wherein n is 1 or 2; R1 and R2 are each independently hydrogen, hydroxy, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy or halogen...	07/08/1997
5639913	Method for preparing optically active 1-aminoindan derivatives Novel derivatives of 1-aminoindan and their salts are described. Optically active 1-aminoindan derivatives are prepared by reacting a N-benzyl analog of the desired compound with an enantiomer of mandelic acid. Parkinson's disease, dementia, epilepsy, con...	06/17/1997
5607969	L-DOPA ethyl ester to treat Parkinson's disease Patients suffering from Parkinson's disease are treated by administering a composition which contains an active ingredient and a pharmaceutically acceptable carrier. The active ingredient comprises L-DOPA ethyl ester in an amount which is at least 97% by ...	03/04/1997
5585358	Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents A compound having the structure: ##STR1## wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1 -C6 alkyl group, an aralkyl group, or an aryl group, and n is an in...	12/17/1996
5576353	Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (...	11/19/1996
5565442	Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3 The invention relates to a process for stabilizing pharmaceutically active derivatives of vitamin D2 and D3. At least one pharmaceutically active vitamin D derivative is dissolved in a solvent with an antioxidant. This solution is mixed with a pharmaceuti...	10/15/1996
5565462	Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative Use of a compound selected from the group consisting of pentoxifylline, propentofylline and torbafylline for topical treatment of psoriasis or atopic dermatitis and pharmaceutical compositions comprising them....	10/15/1996
5532415	R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson'...	07/02/1996
5525631	Compositions of the ethyl ester of L-DOPA A composition which comprises a pharmaceutically acceptable carrier and an active ingredient, such active ingredient comprising L-DOPA ethyl ester derived from its crystaline form in an amount which is at least 97%, by weight, of the active ingredient, an...	06/11/1996
5519061	R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson'...	05/21/1996
5486541	Monofluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase N-propargyl-1-amonoindan monofluorinated in the phenyl ring and their use as selective inhibitors of monoamine oxidase (MAO). There are provided several processes for the preparation of these novel compounds. There are also provided as novel compounds 1-aminoi...	01/23/1996
5484936	Processes for the preparation of 1,3-bis(1,2,4-triazol-1-yl)-propan-2-ol derivatives The invention provides a regiospecific process for the preparation of 1,3-bis(1,2,4-triazol-1-yl)-propan-2-ol derivatives comprising reacting an oxirane acid salt or an oxirane, under acidic conditions, with 4H-4-amino-1,2,4-triazole. The process is parti...	01/16/1996
5457133	R-enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (...	10/10/1995
5453446	Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. R(+)-N-p-opargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (...	09/26/1995
5387612	Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease R(+)-N-propargyl-1-aminoindan, its preparation and use and pharmaceutical compositions containing it. The novel compound was found to be useful for the treatment of human patients for Parkinson's disease, memory disorders, dementia of the Alzheimer type (...	02/07/1995
5354885	Process for preparing ethyl ester of L-DOPA A composition which comprises a pharmaceutically acceptable carrier and an active ingredient, such active ingredient comprising L-DOPA ethyl ester in an amount which is at least 97%, by weight, of the active ingredient, and L-DOPA in an amount which is le...	10/11/1994
5302741	Optical resolution of threo-2-hydroxy-3-(2-aminophenylthio)-3-(4-methoxyphenyl)-propionic acid D(+)-threo-2-hydroxy-3-(2-aminophenylthio)-3-(4-methoxyphenyl)propionic acid, an important intermediate in the synthesis of diltiazem hydrochloride, is obtained in better yields and high optical purity by a novel resolution process comprising the reaction...	04/12/1994
5225585	Production of fluoxetine and new intermediates 4-methyl-3-[(4-trifluormethyl)phenoxy]-3-phenyl propylamine (I) is prepared by reacting 3-dimethylamino-1-phenyl-1-propanol (III) with haloformate (VIII) to obtain a substituted propyl carbamate (IX) which is hydrolyzed under basic conditions to yield met...	07/06/1993
4254128	2-Adamantyl hydrazines and biocidal compositions thereof The invention provides novel 2-adamantyl hydrazine derivatives of the general formula A ##STR1## In this formula R1 is hydrogen or a lower alkyl group of 1-4 carbon atoms; R2 and R3 are the same or different and are e...	03/03/1981
4202892	Biocidal methyladamantyl hydrazines and pharmaceutical compositions containing them The invention provides novel 1- or 2-adamantylmethyl hydrazines of the general formula A ##STR1## In this formula Ad is 1- or 2-adamantyl, R1 and R2 are the same or different and are each hydrogen or a lower unsubstituted or sub...	05/13/1980

PatentStorm

Quotables

PatentStorm News

Assignee: Teva Pharmaceutical Industries Ltd.